Pulse Biosciences, Inc

This stock has a reasonable momentum. Pulse Biosciences, Inc is not a good value stock. Pulse Biosciences, Inc is not very popular among insiders. Pulse Biosciences, Inc is a mediocre stock to choose.
Log in to see more information.
Pulse Biosciences, Inc. is a clinical stage electroceutical, an electrical energy based therapeutic,...
PLSE Fundamental Data by TradingView

News

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nPulse Biosciences just reported results for the second quarter of 2024.\nThe post PLSE Stock Earnings: Pulse Biosciences Reported Results...\n more…

Price T Rowe Associates Inc. MD Invests $88,000 in Pulse Biosciences, Inc. (NASDAQ:PLSE)
Price T Rowe Associates Inc. MD Invests $88,000 in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Ticker Report Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) during the first quarter, according to its most recent disclosure with the...\n more…

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript
Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Seeking Alpha: Transcripts Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript...\n more…

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

Business Wire Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA) technology, today announced...\n more…

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Business Wire Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced the...\n more…

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Business Wire Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced...\n more…